Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Sirolimus

4

XV.e Path: ILD with a granulomatous component (see also Im)

2
Last update : 07/10/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
MTOR inhibitors
5

Publications

Sirolimus-induced pneumonitis following liver transplantation.
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2007 Jun;13;853-6 2007 Jun
Pulmonary toxicity associated with sirolimus treatment in kidney transplantation.
Transplantation proceedings 2006 Oct;38;2438-40 2006 Oct
Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate.
Chest 2006 Jun;129;1718-21 2006 Jun
Patterns of pulmonary complications associated with sirolimus.
Respiration; international review of thoracic diseases 2006;73;367-74 2006
Interstitial granulomatous pneumonitis associated with sirolimus in a child after liver transplantation.
Journal of pediatric gastroenterology and nutrition 2003 Jul;37;91-4 2003 Jul
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
Transplantation 2001 Sep 15;72;787-90 2001 Sep 15

Powered by

  • ^
  • Contact
  • Cookies
  • About